Is Mangoceuticals Worth the Risk? Dive Into Its Volatile Valuation & Struggling Earnings
Investors weigh Mangoceuticals’ tele‑medicine promise against sharp stock swings, a negative P/E, and a low market cap – can the $100 M Solana partnership turn its fortunes?
2 minutes to read
